{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T11:23:57Z","timestamp":1772623437901,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T00:00:00Z","timestamp":1550793600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/51994\/2012"],"award-info":[{"award-number":["SFRH\/BD\/51994\/2012"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Center of Investigation on Environment, Genetics and Oncobiology","award":["Project 18\/12"],"award-info":[{"award-number":["Project 18\/12"]}]},{"name":"FEDER through the Operational Program Competitiveness Factors \u2013 COMPETE and FCT","award":["CNC.IBILI, Center Reference: UID\/NEU\/04539\/2013"],"award-info":[{"award-number":["CNC.IBILI, Center Reference: UID\/NEU\/04539\/2013"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s12032-019-1253-5","type":"journal-article","created":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T11:04:08Z","timestamp":1550833448000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Everolimus in combination with Imatinib overcomes resistance in Chronic myeloid leukaemia"],"prefix":"10.1007","volume":"36","author":[{"given":"Raquel","family":"Alves","sequence":"first","affiliation":[]},{"given":"Ana Cristina","family":"Gon\u00e7alves","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Jorge","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Alves","sequence":"additional","affiliation":[]},{"given":"Ant\u00f3nio","family":"Alves da Silva","sequence":"additional","affiliation":[]},{"given":"Paulo","family":"Freitas-Tavares","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 M.","family":"Nascimento Costa","sequence":"additional","affiliation":[]},{"given":"Ant\u00f3nio M.","family":"Almeida","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4142-4841","authenticated-orcid":false,"given":"Ana B.","family":"Sarmento-Ribeiro","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,2,22]]},"reference":[{"issue":"4","key":"1253_CR1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40291-016-0208-1","volume":"20","author":"MAM Ali","year":"2016","unstructured":"Ali MAM. Chronic myeloid leukemia in the era of tyrosine kinase inhibitors: an evolving paradigm of molecularly targeted therapy. Mol Diagn Therapy. 2016;20(4):315\u201333. \n                    https:\/\/doi.org\/10.1007\/s40291-016-0208-1\n                    \n                  .","journal-title":"Mol Diagn Therapy"},{"key":"1253_CR2","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/ajh.24275","volume":"91","author":"E Jabbour","year":"2016","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am J Hematol. 2016;91:252\u201365. \n                    https:\/\/doi.org\/10.1002\/ajh.24275\n                    \n                  .","journal-title":"Am J Hematol"},{"issue":"1","key":"1253_CR3","first-page":"8","volume":"76","author":"R Frazer","year":"2007","unstructured":"Frazer R, Irvine AE, McMullin MF. Chronic myeloid leukaemia in the 21st century. Ulster Med J. 2007;76(1):8\u201317.","journal-title":"Ulster Med J"},{"issue":"1","key":"1253_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1756-8722-4-6","volume":"4","author":"H Quentmeier","year":"2011","unstructured":"Quentmeier H, Eberth S, Romani J, Zaborski M, Drexler HG. BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance. J Hematol Oncol. 2011;4(1):6. \n                    https:\/\/doi.org\/10.1186\/1756-8722-4-6\n                    \n                  .","journal-title":"J Hematol Oncol"},{"issue":"3","key":"1253_CR5","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.leukres.2014.12.008","volume":"39","author":"R Alves","year":"2015","unstructured":"Alves R, Fonseca AR, Gon\u00e7alves AC, Ferreira-Teixeira M, Lima J, Abrantes AM, et al. Drug transporters play a key role in the complex process of Imatinib resistance in vitro. Leuk Res. 2015;39(3):355\u201360. \n                    https:\/\/doi.org\/10.1016\/j.leukres.2014.12.008\n                    \n                  .","journal-title":"Leuk Res"},{"issue":"4","key":"1253_CR6","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.soc.2013.06.008","volume":"22","author":"B Hassan","year":"2013","unstructured":"Hassan B, Akcakanat A, Holder AM, Meric-Bernstam F. Targeting the PI3-kinase\/Akt\/mTOR signaling pathway. Surg Oncol Clin. 2013;22(4):641\u201364. \n                    https:\/\/doi.org\/10.1016\/j.soc.2013.06.008\n                    \n                  .","journal-title":"Surg Oncol Clin"},{"issue":"2","key":"1253_CR7","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ceb.2009.10.007","volume":"22","author":"A Efeyan","year":"2010","unstructured":"Efeyan A, Sabatini DM. mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol. 2010;22(2):169\u201376. \n                    https:\/\/doi.org\/10.1016\/j.ceb.2009.10.007\n                    \n                  .","journal-title":"Curr Opin Cell Biol"},{"issue":"12","key":"1253_CR8","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1007\/s00018-015-1867-5","volume":"72","author":"J Bertacchini","year":"2015","unstructured":"Bertacchini J, Heidari N, Mediani L, Capitani S, Shahjahani M, Ahmadzadeh A, et al. Targeting PI3K\/AKT\/mTOR network for treatment of leukemia. Cell Mol Life Sci. 2015;72(12):2337\u201347. \n                    https:\/\/doi.org\/10.1007\/s00018-015-1867-5\n                    \n                  .","journal-title":"Cell Mol Life Sci"},{"issue":"8","key":"1253_CR9","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1002\/jcb.25559","volume":"117","author":"S Dinner","year":"2016","unstructured":"Dinner S, Platanias LC. Targeting the mTOR pathway in leukemia. J Cell Biochem. 2016;117(8):1745\u201352. \n                    https:\/\/doi.org\/10.1002\/jcb.25559\n                    \n                  .","journal-title":"J Cell Biochem"},{"key":"1253_CR10","doi-asserted-by":"publisher","unstructured":"Burchert A, Wang Y, Cai D, von Bubnoff N, Paschka P, M\u00fcller-Br\u00fcsselbach S, et al. Compensatory PI3-kinase\/Akt\/mTor activation regulates imatinib resistance development. Leukemia. 2005;19:1774\u201382. \n                    https:\/\/doi.org\/10.1038\/sj.leu.2403898\n                    \n                  . \n                    https:\/\/www.nature.com\/articles\/2403898#supplementary-information\n                    \n                  .","DOI":"10.1038\/sj.leu.2403898"},{"key":"1253_CR11","doi-asserted-by":"publisher","unstructured":"Mitchell R, Hopcroft LEM, Baquero P, Allan EK, Hewit K, James D, et al. Targeting BCR-ABL-independent TKI resistance in chronic myeloid leukemia by mTOR and autophagy inhibition. JNCI: J Natl Cancer Inst. 2017:djx236\u2013djx. \n                    https:\/\/doi.org\/10.1093\/jnci\/djx236\n                    \n                  .","DOI":"10.1093\/jnci\/djx236"},{"issue":"1","key":"1253_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2012.01.005","volume":"319","author":"YY Zaytseva","year":"2012","unstructured":"Zaytseva YY, Valentino JD, Gulhati P, Mark Evers B. mTOR inhibitors in cancer therapy. Cancer Lett. 2012;319(1):1\u20137. \n                    https:\/\/doi.org\/10.1016\/j.canlet.2012.01.005\n                    \n                  .","journal-title":"Cancer Lett"},{"issue":"17","key":"1253_CR13","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1158\/1078-0432.ccr-06-0764","volume":"12","author":"KWL Yee","year":"2006","unstructured":"Yee KWL, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, et al. Phase I\/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2006;12(17):5165\u201373. \n                    https:\/\/doi.org\/10.1158\/1078-0432.ccr-06-0764\n                    \n                  .","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1253_CR14","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s12253-015-9998-4","volume":"22","author":"J Mendes","year":"2016","unstructured":"Mendes J, Gon\u00e7alves AC, Alves R, Jorge J, Pires A, Ribeiro A, et al. L744,832 and everolimus induce cytotoxic and cytostatic effects in non-hodgkin lymphoma cells. Pathol Oncol Res. 2016;22(2):301\u20139. \n                    https:\/\/doi.org\/10.1007\/s12253-015-9998-4\n                    \n                  .","journal-title":"Pathol Oncol Res"},{"key":"1253_CR15","first-page":"61","volume-title":"The median-effect principle and the combination index for quantitation of synergism and antagonism. Synergism and antagonism in chemotherapy","author":"T Chou","year":"1991","unstructured":"Chou T. The median-effect principle and the combination index for quantitation of synergism and antagonism. Synergism and antagonism in chemotherapy. San Diego: Academic Press; 1991. pp.\u00a061\u2013102."},{"key":"1253_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27\u201355.","journal-title":"Adv Enzyme Regul"},{"issue":"3","key":"1253_CR17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.drup.2008.03.001","volume":"11","author":"B-H Jiang","year":"2008","unstructured":"Jiang B-H, Liu L-Z. Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist Updates. 2008;11(3):63\u201376. \n                    https:\/\/doi.org\/10.1016\/j.drup.2008.03.001\n                    \n                  .","journal-title":"Drug Resist Updates"},{"issue":"22","key":"1253_CR18","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1182\/blood.V128.22.1119.1119","volume":"128","author":"CA Eide","year":"2016","unstructured":"Eide CA, Bottomly D, Savage SL, White L, Wilmot B, Reister Schultz AM, et al. Characterization of the genomic landscape of BCR-ABL1 kinase-independent mechanisms of resistance to ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia. Blood. 2016;128(22):1119-.","journal-title":"Blood"},{"issue":"19","key":"1253_CR19","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim D-W, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in philadelphia chromosome\u2013positive leukemias. N Engl J Med. 2013;369(19):1783\u201396. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1306494\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"2","key":"1253_CR20","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/jcb.22380","volume":"109","author":"M Mancini","year":"2010","unstructured":"Mancini M, Petta S, Martinelli G, Barbieri E, Santucci MA. RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia. J Cell Biochem. 2010;109(2):320\u20138. \n                    https:\/\/doi.org\/10.1002\/jcb.22380\n                    \n                  .","journal-title":"J Cell Biochem"},{"issue":"2","key":"1253_CR21","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/ejh.12202","volume":"92","author":"X Yang","year":"2014","unstructured":"Yang X, He G, Gong Y, Zheng B, Shi F, Shi R, et al. Mammalian target of rapamycin inhibitor rapamycin enhances anti-leukemia effect of imatinib on Ph + acute lymphoblastic leukemia cells. Eur J Haematol. 2014;92(2):111\u201320. \n                    https:\/\/doi.org\/10.1111\/ejh.12202\n                    \n                  . doi.","journal-title":"Eur J Haematol"},{"issue":"8","key":"1253_CR22","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1182\/blood-2006-06-030833","volume":"109","author":"Z Zeng","year":"2007","unstructured":"Zeng Z, Sarbassov DD, Samudio IJ, Yee KWL, Munsell MF, Ellen Jackson C, et al. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood. 2007;109(8):3509\u201312. \n                    https:\/\/doi.org\/10.1182\/blood-2006-06-030833\n                    \n                  .","journal-title":"Blood"},{"issue":"23","key":"1253_CR23","first-page":"8451","volume":"63","author":"AL Edinger","year":"2003","unstructured":"Edinger AL, Linardic CM, Chiang GG, Thompson CB, Abraham RT. Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. Can Res. 2003;63(23):8451\u201360.","journal-title":"Can Res"},{"issue":"7","key":"1253_CR24","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1080\/15384101.2015.1006970","volume":"14","author":"A Morotti","year":"2015","unstructured":"Morotti A, Panuzzo C, Crivellaro S, Carr\u00e0 G, Fava C, Guerrasio A, et al. BCR-ABL inactivates cytosolic PTEN through casein kinase II mediated tail phosphorylation. Cell Cycle. 2015;14(7):973\u20139. \n                    https:\/\/doi.org\/10.1080\/15384101.2015.1006970\n                    \n                  .","journal-title":"Cell Cycle"},{"issue":"3","key":"1253_CR25","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1182\/blood-2009-06-228130","volume":"115","author":"C Peng","year":"2010","unstructured":"Peng C, Chen Y, Yang Z, Zhang H, Osterby L, Rosmarin AG, et al. PTEN is a tumor suppressor in CML stem cells and BCR-ABL\u2013induced leukemias in mice. Blood. 2010;115(3):626\u201335. \n                    https:\/\/doi.org\/10.1182\/blood-2009-06-228130\n                    \n                  .","journal-title":"Blood"},{"issue":"5","key":"1253_CR26","first-page":"1602","volume":"5","author":"P Xia","year":"2015","unstructured":"Xia P, Xu X-Y. PI3K\/Akt\/mTOR signaling pathway in cancer stem cells: from basic research to clinical application. Am J Cancer Res. 2015;5(5):1602\u20139.","journal-title":"Am J Cancer Res"},{"issue":"11","key":"1253_CR27","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1002\/stem.521","volume":"28","author":"J Sunayama","year":"2010","unstructured":"Sunayama J, Matsuda K-I, Sato A, Tachibana K, Suzuki K, Narita Y, et al. Crosstalk between the PI3K\/mTOR and MEK\/ERK pathways Involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells. Stem Cells. 2010;28(11):1930\u20139. \n                    https:\/\/doi.org\/10.1002\/stem.521\n                    \n                  .","journal-title":"Stem Cells"},{"key":"1253_CR28","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3389\/fonc.2014.00108","volume":"4","author":"SK Tasian","year":"2014","unstructured":"Tasian SK, Teachey DT, Rheingold SR. Targeting the PI3K\/mTOR pathway in pediatric hematologic malignancies. Front Oncol. 2014;4:108. \n                    https:\/\/doi.org\/10.3389\/fonc.2014.00108\n                    \n                  .","journal-title":"Front Oncol"},{"issue":"6","key":"1253_CR29","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1182\/blood-2004-06-2494","volume":"105","author":"C R\u00e9cher","year":"2005","unstructured":"R\u00e9cher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos Santos C, Mas VM-D, et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood. 2005;105(6):2527\u201334. \n                    https:\/\/doi.org\/10.1182\/blood-2004-06-2494\n                    \n                  .","journal-title":"Blood"},{"key":"1253_CR30","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/nm0901-1028","volume":"7","author":"S Zhou","year":"2001","unstructured":"Zhou S, Schuetz JD, Bunting KD, Colapietro A-M, Sampath J, Morris JJ, et al. The ABC transporter Bcrp1\/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med. 2001;7:1028\u201334. \n                    https:\/\/doi.org\/10.1038\/nm0901-1028\n                    \n                  .","journal-title":"Nat Med"},{"issue":"3","key":"1253_CR31","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.stem.2009.01.007","volume":"4","author":"A-M Bleau","year":"2009","unstructured":"Bleau A-M, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, et al. PTEN\/PI3K\/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell. 2009;4(3):226\u201335. \n                    https:\/\/doi.org\/10.1016\/j.stem.2009.01.007\n                    \n                  .","journal-title":"Cell Stem Cell"},{"issue":"1","key":"1253_CR32","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.canlet.2013.04.006","volume":"336","author":"F-F Huang","year":"2013","unstructured":"Huang F-F, Wu D-S, Zhang L, Yu Y-H, Yuan X-Y, Li W-J, et al. Inactivation of PTEN increases ABCG2 expression and the side population through the PI3K\/Akt pathway in adult acute leukemia. Cancer Lett. 2013;336(1):96\u2013105. \n                    https:\/\/doi.org\/10.1016\/j.canlet.2013.04.006\n                    \n                  .","journal-title":"Cancer Lett"},{"issue":"3","key":"1253_CR33","doi-asserted-by":"publisher","first-page":"e88298","DOI":"10.1371\/journal.pone.0088298","volume":"9","author":"F-F Huang","year":"2014","unstructured":"Huang F-F, Zhang L, Wu D-S, Yuan X-Y, Chen F-P, Zeng H, et al. PTEN regulates BCRP\/ABCG2 and the side population through the PI3K\/Akt pathway in chronic myeloid leukemia. PLoS ONE. 2014;9(3):e88298. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0088298\n                    \n                  .","journal-title":"PLoS ONE"},{"issue":"4","key":"1253_CR34","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.bbrc.2012.03.090","volume":"420","author":"C Heged\u00fcs","year":"2012","unstructured":"Heged\u00fcs C, Truta-Feles K, Antalffy G, Br\u00f3zik A, Kasza I, N\u00e9met K, et al. PI3-kinase and mTOR inhibitors differently modulate the function of the ABCG2 multidrug transporter. Biochem Biophys Res Commun. 2012;420(4):869\u201374. \n                    https:\/\/doi.org\/10.1016\/j.bbrc.2012.03.090\n                    \n                  .","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"1253_CR35","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1111\/bph.12183","volume":"169","author":"A Sinclair","year":"2013","unstructured":"Sinclair A, Latif AL, Holyoake TL. Targeting survival pathways in chronic myeloid leukaemia stem cells. Br J Pharmacol. 2013;169(8):1693\u2013707. \n                    https:\/\/doi.org\/10.1111\/bph.12183\n                    \n                  .","journal-title":"Br J Pharmacol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-019-1253-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-019-1253-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-019-1253-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T19:24:39Z","timestamp":1582313079000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-019-1253-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,22]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["1253"],"URL":"https:\/\/doi.org\/10.1007\/s12032-019-1253-5","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,22]]},"assertion":[{"value":"10 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"30"}}